Bringing Hope to Life
Senhwa is a precision therapy company focusing on developing First-in-Class therapeutics for patients with unmet medical needs. These include multiple programs for gene-mutated cancers, rare diseases, and novel coronaviruses.
The first patient treated with Senhwa’s Silmitasertib (CX-4945) for severe COVID-19 demonstrated remarkable recovery and was discharged in 5 days after treatment.
OUR CLINICAL TRIALS
One Drug with Multi-target Therapy
Senhwa’s Pidnarulex (CX-5461) has proven to be the next generation DDR (DNA Damage Response) drug, with the mechanism of synthetic lethality across multiple tumor types in patients with loss of function of tumor suppressor genes such as HRD (Homologous Recombination Deficiency) and beyond, and has great potential for patients who have developed resistance to PARP inhibitors and platinum or other chemotherapies.
Pioneering the Paradigm
Senhwa strives to design and develop innovative therapies rooted in our leading expertise in protein kinases inhibition, and improve quality of life for cancer patients. .
August 25, 2023
Senhwa Biosciences Completes Last Patient Last Visit in the Phase I Expansion Study for Advanced Basal Cell Carcinoma with its Lead Drug Candidate Silmitasertib
April 28, 2023
Senhwa Biosciences Received Taiwan FDA IND Approval for Phase II Study of Silmitasertib in Patients with Moderate to Severe COVID-19
Media and Events
December 01, 2022
Senhwa Biosciences Announces Successful Awardee of Anticancer Pipeline, Pidnarulex, in NIH-Sponsored NExT Program
March 28, 2022
At the 2022 AAD Annual Meeting, Senhwa Presents Positive Initial Data from Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma
Senhwa Biosciences' drug product, Silmitasertib (CX-4945), blocks CK2- potentially stopping SARS-Cov-2 in its tracks
Basal Cell Carcinoma
Potential therapeutic against novel coronavirus
Targeted therapy against solid tumors with BRCA2 or PALB2 mutations.
Potential therapeutic for PAPRi or other chemotherapies resistant patients.
Potential for combined use with immunotherapy
Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study
“As a value added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through to clinical Proof of Concept”
- Dr. Jin-Ding Huang , CEO